Champions Oncology (CSBR) Asset Writedowns and Impairment (2015 - 2026)
Champions Oncology (CSBR) posted quarterly Asset Writedowns and Impairment of $74000.0 for Q2 2026, up 54.17% year-over-year from $48000.0 in Q2 2025, and up 346.67% quarter-over-quarter from -$30000.0 in Q1 2026.
Champions Oncology (CSBR) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Champions Oncology's Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at $74000.0 for Q2 2026.
- In Q2 2026, Asset Writedowns and Impairment rose 54.17% year-over-year to $74000.0; the TTM figure through Apr 2026 stood at $28000.0 (up 110.29% YoY), while the FY2026 annual figure was $28000.0, up 110.29% from the prior year.
- Asset Writedowns and Impairment for Q2 2026 stood at $74000.0, up from -$30000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $724000.0 in Q2 2023, with the low at -$209000.0 in Q4 2024.
- The 5-year median for Asset Writedowns and Impairment is $48000.0 (2025), against an average of $69266.7.
- Peak annual rise in Asset Writedowns and Impairment reached 270.21% in 2024, while the deepest fall reached 390.28% in 2024.
- Champions Oncology's Asset Writedowns and Impairment stood at $130000.0 in 2022, then tumbled by 44.62% to $72000.0 in 2023, then sank by 390.28% to -$209000.0 in 2024, then jumped by 106.22% to $13000.0 in 2025, then jumped by 469.23% to $74000.0 in 2026.
- Business Quant data shows CSBR's Asset Writedowns and Impairment at $74000.0 in Q2 2026, -$30000.0 in Q1 2026, and $13000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 74,000.00 |
| Apr 30, 2026 | 74,000.00 |
| Jan 31, 2026 | -30,000.00 |
| Jan 31, 2026 | -30,000.00 |
| Oct 31, 2025 | 13,000.00 |
| Oct 31, 2025 | 13,000.00 |
| Jul 31, 2025 | -29,000.00 |
| Jul 31, 2025 | -29,000.00 |
| Apr 30, 2025 | 48,000.00 |
| Apr 30, 2025 | 48,000.00 |
| Jan 31, 2025 | -40,000.00 |
| Jan 31, 2025 | -40,000.00 |
| Oct 31, 2024 | -209,000.00 |
| Oct 31, 2024 | -209,000.00 |
| Jul 31, 2024 | -71,000.00 |
| Jul 31, 2024 | -71,000.00 |
| Apr 30, 2024 | 162,000.00 |
| Apr 30, 2024 | 162,000.00 |
| Jan 31, 2024 | 80,000.00 |
| Jan 31, 2024 | 80,000.00 |